1
|
Kersten K, You R, Liang S, Tharp KM, Pollack J, Weaver VM, Krummel MF, Headley MB. Uptake of tumor-derived microparticles induces metabolic reprogramming of macrophages in the early metastatic lung. Cell Rep 2023; 42:112582. [PMID: 37261951 PMCID: PMC10592447 DOI: 10.1016/j.celrep.2023.112582] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 03/30/2023] [Accepted: 05/16/2023] [Indexed: 06/03/2023] Open
Abstract
Pre-metastatic niche formation is a critical step during the metastatic spread of cancer. One way by which primary tumors prime host cells at future metastatic sites is through the shedding of tumor-derived microparticles as a consequence of vascular sheer flow. However, it remains unclear how the uptake of such particles by resident immune cells affects their phenotype and function. Here, we show that ingestion of tumor-derived microparticles by macrophages induces a rapid metabolic and phenotypic switch that is characterized by enhanced mitochondrial mass and function, increased oxidative phosphorylation, and upregulation of adhesion molecules, resulting in reduced motility in the early metastatic lung. This reprogramming event is dependent on signaling through the mTORC1, but not the mTORC2, pathway and is induced by uptake of tumor-derived microparticles. Together, these data support a mechanism by which uptake of tumor-derived microparticles induces reprogramming of macrophages to shape their fate and function in the early metastatic lung.
Collapse
Affiliation(s)
- Kelly Kersten
- Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA; ImmunoX Initiative, University of California San Francisco, San Francisco, CA 94143, USA
| | - Ran You
- Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA; ImmunoX Initiative, University of California San Francisco, San Francisco, CA 94143, USA
| | - Sophia Liang
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Kevin M Tharp
- Center for Bioengineering and Tissue Regeneration, Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA
| | - Joshua Pollack
- ImmunoX Initiative, University of California San Francisco, San Francisco, CA 94143, USA; Foundery Innovations, San Francisco, CA 94080, USA
| | - Valerie M Weaver
- Center for Bioengineering and Tissue Regeneration, Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA
| | - Matthew F Krummel
- Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA; ImmunoX Initiative, University of California San Francisco, San Francisco, CA 94143, USA; Foundery Innovations, San Francisco, CA 94080, USA
| | - Mark B Headley
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Immunology, University of Washington, Seattle, WA 98109, USA.
| |
Collapse
|
2
|
Becht E, Tolstrup D, Dutertre CA, Morawski PA, Campbell DJ, Ginhoux F, Newell EW, Gottardo R, Headley MB. High-throughput single-cell quantification of hundreds of proteins using conventional flow cytometry and machine learning. Sci Adv 2021; 7:eabg0505. [PMID: 34550730 PMCID: PMC8457665 DOI: 10.1126/sciadv.abg0505] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Accepted: 07/14/2021] [Indexed: 06/03/2023]
Abstract
Modern immunologic research increasingly requires high-dimensional analyses to understand the complex milieu of cell types that comprise the tissue microenvironments of disease. To achieve this, we developed Infinity Flow combining hundreds of overlapping flow cytometry panels using machine learning to enable the simultaneous analysis of the coexpression patterns of hundreds of surface-expressed proteins across millions of individual cells. In this study, we demonstrate that this approach allows the comprehensive analysis of the cellular constituency of the steady-state murine lung and the identification of previously unknown cellular heterogeneity in the lungs of melanoma metastasis–bearing mice. We show that by using supervised machine learning, Infinity Flow enhances the accuracy and depth of clustering or dimensionality reduction algorithms. Infinity Flow is a highly scalable, low-cost, and accessible solution to single-cell proteomics in complex tissues.
Collapse
Affiliation(s)
- Etienne Becht
- Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Daniel Tolstrup
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Charles-Antoine Dutertre
- Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore
- Program in Emerging Infectious Disease, Duke-NUS Medical School, Singapore, Singapore
- Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Center, Singapore 169856, Singapore
| | - Peter A. Morawski
- Center for Fundamental Immunology, Benaroya Research Institute, Seattle, WA, USA
| | - Daniel J. Campbell
- Center for Fundamental Immunology, Benaroya Research Institute, Seattle, WA, USA
- Department of Immunology, University of Washington School of Medicine, Seattle, WA, USA
| | - Florent Ginhoux
- Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore
- Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Center, Singapore 169856, Singapore
- Shanghai Institute of Immunology, Shanghai JiaoTong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, China
| | - Evan W. Newell
- Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Raphael Gottardo
- Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Mark B. Headley
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Department of Immunology, University of Washington School of Medicine, Seattle, WA, USA
| |
Collapse
|
3
|
Dodagatta-Marri E, Ma HY, Liang B, Li J, Meyer DS, Chen SY, Sun KH, Ren X, Zivak B, Rosenblum MD, Headley MB, Pinzas L, Reed NI, Del Cid JS, Hann BC, Yang S, Giddabasappa A, Noorbehesht K, Yang B, Dal Porto J, Tsukui T, Niessen K, Atakilit A, Akhurst RJ, Sheppard D. Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy. Cell Rep 2021; 36:109309. [PMID: 34233193 PMCID: PMC8321414 DOI: 10.1016/j.celrep.2021.109309] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Revised: 01/17/2021] [Accepted: 06/04/2021] [Indexed: 01/18/2023] Open
Abstract
αvβ8 integrin, a key activator of transforming growth factor β (TGF-β), inhibits anti-tumor immunity. We show that a potent blocking monoclonal antibody against αvβ8 (ADWA-11) causes growth suppression or complete regression in syngeneic models of squamous cell carcinoma, mammary cancer, colon cancer, and prostate cancer, especially when combined with other immunomodulators or radiotherapy. αvβ8 is expressed at the highest levels in CD4+CD25+ T cells in tumors, and specific deletion of β8 from T cells is as effective as ADWA-11 in suppressing tumor growth. ADWA-11 increases expression of a suite of genes in tumor-infiltrating CD8+ T cells normally inhibited by TGF-β and involved in tumor cell killing, including granzyme B and interferon-γ. The in vitro cytotoxic effect of tumor CD8 T cells is inhibited by CD4+CD25+ cells, and this suppressive effect is blocked by ADWA-11. These findings solidify αvβ8 integrin as a promising target for cancer immunotherapy. TGF-β suppresses anti-tumor immunity. Dodagatta-Marri, Ma et al. show that the TGF-β-activating integrin αvβ8 is expressed on CD25+CD4+ tumor T cells and suppresses anti-tumor immunity by CD8+ T cells. Blocking this integrin enhances tumor cell killing and synergizes with multiple immune modulators or radiotherapy to induce long-term anti-tumor immunity.
Collapse
Affiliation(s)
- Eswari Dodagatta-Marri
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA
| | - Hsiao-Yen Ma
- Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Benjia Liang
- Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
| | - John Li
- Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Dominique S Meyer
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA
| | - Szu-Ying Chen
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA
| | - Kai-Hui Sun
- Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Xin Ren
- Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Bahar Zivak
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA
| | - Michael D Rosenblum
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA
| | - Mark B Headley
- Department of Pathology, University of California, San Francisco, San Francisco, CA, USA
| | - Lauren Pinzas
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA
| | - Nilgun I Reed
- Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Joselyn S Del Cid
- Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Byron C Hann
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA
| | - Sharon Yang
- Comparative Medicine, Pfizer Inc., San Diego, CA, USA
| | | | | | - Bing Yang
- Oncology Research Unit, Pfizer Inc., Pearl River, NY, USA
| | - Joseph Dal Porto
- Pfizer Centers for Therapeutic Innovation, San Francisco, CA, USA
| | - Tatsuya Tsukui
- Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Kyle Niessen
- Pfizer Centers for Therapeutic Innovation, San Francisco, CA, USA
| | - Amha Atakilit
- Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Rosemary J Akhurst
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA; Department of Anatomy, University of California, San Francisco, San Francisco, CA, USA.
| | - Dean Sheppard
- Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
| |
Collapse
|
4
|
Abstract
The response to the COVID-19 crisis across most research institutions mandated ceasing nonessential research activities in order to minimize the spread of the virus in our communities. With minimal notice, experiments were terminated, cell lines were frozen, mouse colonies were culled, and trainees were prevented from performing bench research. Still, despite the interruption of experimental productivity, the shutdown has proven for many PIs and trainees that doing and thinking science are not activities that are bound to the laboratory. Furthermore, the shutdowns have solidified important emerging trends and forced us to further innovate to get the most out of working remotely. We hope that some of these innovations, hard-gained in this difficult time, will persist and develop into new paradigms-lessons that will improve our science and our relationship to the climate and community beyond the current pandemic.
Collapse
Affiliation(s)
- Tanya S. Freedman
- Department of Pharmacology, Center for Immunology, Masonic Cancer Center, Center for Autoimmune Diseases Research, University of Minnesota, Minneapolis, MN
| | - Mark B. Headley
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
- Department of Immunology, University of Washington School of Medicine, Seattle, WA
| | - Nina Serwas
- Department of Pathology, University of California, San Francisco, San Francisco, CA
- University of California, San Francisco ImmunoX Initiative, University of California, San Francisco, San Francisco, CA
| | - Megan Ruhland
- Department of Pathology, University of California, San Francisco, San Francisco, CA
- University of California, San Francisco ImmunoX Initiative, University of California, San Francisco, San Francisco, CA
| | - Carlos A. Castellanos
- University of California, San Francisco ImmunoX Initiative, University of California, San Francisco, San Francisco, CA
- Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA
| | - Alexis J. Combes
- Department of Pathology, University of California, San Francisco, San Francisco, CA
- University of California, San Francisco ImmunoX Initiative, University of California, San Francisco, San Francisco, CA
- University of California, San Francisco CoLabs, University of California, San Francisco, San Francisco, CA
| | - Matthew F. Krummel
- Department of Pathology, University of California, San Francisco, San Francisco, CA
- University of California, San Francisco ImmunoX Initiative, University of California, San Francisco, San Francisco, CA
| |
Collapse
|
5
|
Puttur F, Denney L, Gregory LG, Vuononvirta J, Oliver R, Entwistle LJ, Walker SA, Headley MB, McGhee EJ, Pease JE, Krummel MF, Carlin LM, Lloyd CM. Pulmonary environmental cues drive group 2 innate lymphoid cell dynamics in mice and humans. Sci Immunol 2019; 4:eaav7638. [PMID: 31175176 PMCID: PMC6744282 DOI: 10.1126/sciimmunol.aav7638] [Citation(s) in RCA: 78] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Accepted: 04/09/2019] [Indexed: 12/11/2022]
Abstract
Group 2 innate lymphoid cells (ILC2s) are enriched in mucosal tissues (e.g., lung) and respond to epithelial cell-derived cytokines initiating type 2 inflammation. During inflammation, ILC2 numbers are increased in the lung. However, the mechanisms controlling ILC2 trafficking and motility within inflamed lungs remain unclear and are crucial for understanding ILC2 function in pulmonary immunity. Using several approaches, including lung intravital microscopy, we demonstrate that pulmonary ILC2s are highly dynamic, exhibit amoeboid-like movement, and aggregate in the lung peribronchial and perivascular spaces. They express distinct chemokine receptors, including CCR8, and actively home to CCL8 deposits located around the airway epithelium. Within lung tissue, ILC2s were particularly motile in extracellular matrix-enriched regions. We show that collagen-I drives ILC2 to markedly change their morphology by remodeling their actin cytoskeleton to promote environmental exploration critical for regulating eosinophilic inflammation. Our study provides previously unappreciated insights into ILC2 migratory patterns during inflammation and highlights the importance of environmental guidance cues in the lung in controlling ILC2 dynamics.
Collapse
Affiliation(s)
- Franz Puttur
- Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK
| | - Laura Denney
- Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK
| | - Lisa G Gregory
- Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK
| | - Juho Vuononvirta
- Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK
| | - Robert Oliver
- Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK
| | - Lewis J Entwistle
- Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK
| | - Simone A Walker
- Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK
| | - Mark B Headley
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Ewan J McGhee
- Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow, UK
| | - James E Pease
- Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK
| | - Matthew F Krummel
- Department of Pathology, University of California, San Francisco, 513 Parnassus Ave., San Francisco, CA, USA
| | - Leo M Carlin
- Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK.
- Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow, UK
- Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - Clare M Lloyd
- Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London, London, UK.
| |
Collapse
|
6
|
Looney MR, Headley MB. Live imaging of the pulmonary immune environment. Cell Immunol 2018; 350:103862. [PMID: 30336937 DOI: 10.1016/j.cellimm.2018.09.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2018] [Revised: 07/12/2018] [Accepted: 09/27/2018] [Indexed: 01/22/2023]
Abstract
The lung represents a unique immune environment. The primary function of the lung is to enable gas exchange by facilitating the transfer of oxygen into and carbon dioxide out of the blood. However, as a direct byproduct of this process the lung is also constantly exposed to particles, allergens, and pathogens alongside air itself. Due to this, the pulmonary immune system exists in a fine balance between quiescence and inflammation, deviations from which can lead to a failure in respiratory function. A rich history exists attempting to define the critical features of lung immunity, and most recently advances in intravital microscopy have enabled the visualization of intercellular immune dynamics in both steady-state and a variety of disease conditions. In this review, we will summarize a variety of approaches to intravital lung imaging as well as how its application has advanced our understanding of normal lung function as well as disease states such as pulmonary metastasis, asthma, and lung injury.
Collapse
Affiliation(s)
- Mark R Looney
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94143, USA; Department of Laboratory Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94143, USA
| | - Mark B Headley
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
| |
Collapse
|
7
|
Morrissey MA, Williamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, Vale RD. Chimeric antigen receptors that trigger phagocytosis. eLife 2018; 7:36688. [PMID: 29862966 PMCID: PMC6008046 DOI: 10.7554/elife.36688] [Citation(s) in RCA: 176] [Impact Index Per Article: 29.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Accepted: 05/26/2018] [Indexed: 12/14/2022] Open
Abstract
Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill cancer. The success of CAR-T cell therapies highlights the promise of programmed immunity and suggests that applying CAR strategies to other immune cell lineages may be beneficial. Here, we engineered a family of Chimeric Antigen Receptors for Phagocytosis (CAR-Ps) that direct macrophages to engulf specific targets, including cancer cells. CAR-Ps consist of an extracellular antibody fragment, which can be modified to direct CAR-P activity towards specific antigens. By screening a panel of engulfment receptor intracellular domains, we found that the cytosolic domains from Megf10 and FcRɣ robustly triggered engulfment independently of their native extracellular domain. We show that CAR-Ps drive specific engulfment of antigen-coated synthetic particles and whole human cancer cells. Addition of a tandem PI3K recruitment domain increased cancer cell engulfment. Finally, we show that CAR-P expressing murine macrophages reduce cancer cell number in co-culture by over 40%. Our immune system constantly patrols our body, looking to eliminate cancerous cells and harmful microbes. It can spot these threats because it recognizes certain signals at the surface of dangerous cells. However, cancer cells often find ways to ‘hide’ from our immune system. Chimeric antigen receptors, or CARs, are receptors designed in a laboratory to attach to specific proteins that are found on a cancer cell. These receptors tell immune cells, such as T cells, to attack cancers. T cells that carry CARs are already used to treat people with blood cancers. Yet, these immune cells are not good at penetrating a solid tumor to kill the cells inside, which limits their use. Macrophages are a group of immune cells that can make their way inside tumors and travel to cancers that the rest of the immune system cannot reach. They defend our body by ‘swallowing’ harmful cells. Would it then be possible to use CARs to program macrophages to ‘eat’ cancer cells? Morrissey, Williamson et al. created a new type of CARs, named CAR-P, and introduced it in macrophages. These cells were then able to recognize and attack beads covered in proteins found on cancer cells. The modified macrophages could also limit the growth of live cancer cells in a dish by ‘biting’ and even ‘eating’ them. While these results are promising in the laboratory, the next step is to test whether these reprogrammed macrophages can recognize and fight cancers in living animals.
Collapse
Affiliation(s)
- Meghan A Morrissey
- Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.,Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, United States
| | - Adam P Williamson
- Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.,Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, United States
| | - Adriana M Steinbach
- Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.,Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, United States
| | - Edward W Roberts
- Department of Pathology, University of California, San Francisco, San Francisco, United States
| | - Nadja Kern
- Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.,Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, United States
| | - Mark B Headley
- Department of Pathology, University of California, San Francisco, San Francisco, United States
| | - Ronald D Vale
- Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.,Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, United States
| |
Collapse
|
8
|
Lefrançais E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, Thornton EE, Headley MB, David T, Coughlin SR, Krummel MF, Leavitt AD, Passegué E, Looney MR. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature 2017; 544:105-109. [PMID: 28329764 PMCID: PMC5663284 DOI: 10.1038/nature21706] [Citation(s) in RCA: 684] [Impact Index Per Article: 97.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2016] [Accepted: 02/14/2017] [Indexed: 12/13/2022]
Abstract
Platelets are critical for haemostasis, thrombosis, and inflammatory responses, but the events that lead to mature platelet production remain incompletely understood. The bone marrow has been proposed to be a major site of platelet production, although there is indirect evidence that the lungs might also contribute to platelet biogenesis. Here, by directly imaging the lung microcirculation in mice, we show that a large number of megakaryocytes circulate through the lungs, where they dynamically release platelets. Megakaryocytes that release platelets in the lungs originate from extrapulmonary sites such as the bone marrow; we observed large megakaryocytes migrating out of the bone marrow space. The contribution of the lungs to platelet biogenesis is substantial, accounting for approximately 50% of total platelet production or 10 million platelets per hour. Furthermore, we identified populations of mature and immature megakaryocytes along with haematopoietic progenitors in the extravascular spaces of the lungs. Under conditions of thrombocytopenia and relative stem cell deficiency in the bone marrow, these progenitors can migrate out of the lungs, repopulate the bone marrow, completely reconstitute blood platelet counts, and contribute to multiple haematopoietic lineages. These results identify the lungs as a primary site of terminal platelet production and an organ with considerable haematopoietic potential.
Collapse
Affiliation(s)
- Emma Lefrançais
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| | - Guadalupe Ortiz-Muñoz
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| | - Axelle Caudrillier
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| | - Beñat Mallavia
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| | - Fengchun Liu
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| | - David M. Sayah
- Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California 90095, USA
| | - Emily E. Thornton
- Department of Pathology, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| | - Mark B. Headley
- Department of Pathology, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| | - Tovo David
- Cardiovascular Research Institute, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| | - Shaun R. Coughlin
- Cardiovascular Research Institute, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| | - Matthew F. Krummel
- Department of Pathology, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| | - Andrew D. Leavitt
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| | - Emmanuelle Passegué
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| | - Mark R. Looney
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
- Department of Laboratory Medicine, University of California, San Francisco (UCSF), San Francisco, California 94143, USA
| |
Collapse
|
9
|
Roberts EW, Headley MB, Broz M, Boldjipour B, Corbin K, Binnewies M, Bins A, Gerard AA, Krummel M. Abstract IA32: Visualizing tumor immune interaction in real time. Cancer Immunol Res 2016. [DOI: 10.1158/2326-6066.imm2016-ia32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The nature of an immune response is rarely defined by a unanimous decisions by the participating cells; cells with seemingly opposing functions pervade many immune sites and tumors are no exception. Multiple DC and Macrophage subsets exert push/pull on T cell responses in tumors. Fundamentals of this are gleaned by live-imaging in connection with conventional methods such as flow-cytometry and immunofluorescence. Here, we broadly treat real-time imaging as a discovery tool to understand the tumor microenvironment (TME) and the diversity of cellular interactions that comprise host-tumor interactions. We have advanced this technology from sites of primary, spontaneous and aggressive tumors into sites of metastasis. The results promote the concept of seeking “allies” for tumor therapies within the TME and provide a basis for considering the balance of push/pull signals that determine the consensus immune response.
Citation Format: Edward W. Roberts, Mark B. Headley, Miranda Broz, Bijan Boldjipour, Kaitlin Corbin, Mikhail Binnewies, Adriaan Bins, Audrey Audrey Gerard, Matthew Krummel. Visualizing tumor immune interaction in real time [abstract]. In: Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; 2016 Sept 25-28; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(11 Suppl):Abstract nr IA32.
Collapse
Affiliation(s)
| | | | - Miranda Broz
- 2University of California and Precision Immune Inc., San Francisco, CA
| | | | | | - Mikhail Binnewies
- 2University of California and Precision Immune Inc., San Francisco, CA
| | - Adriaan Bins
- 3University of California and Netherlands Cancer Institute, San Francisco, CA
| | | | | |
Collapse
|
10
|
Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, Kaisho T, Bogunovic D, Bhardwaj N, Krummel MF. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell 2016; 30:324-336. [PMID: 27424807 PMCID: PMC5374862 DOI: 10.1016/j.ccell.2016.06.003] [Citation(s) in RCA: 638] [Impact Index Per Article: 79.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2015] [Revised: 02/08/2016] [Accepted: 06/04/2016] [Indexed: 12/24/2022]
Abstract
Intratumoral dendritic cells (DC) bearing CD103 in mice or CD141 in humans drive intratumoral CD8(+) T cell activation. Using multiple strategies, we identified a critical role for these DC in trafficking tumor antigen to lymph nodes (LN), resulting in both direct CD8(+) T cell stimulation and antigen hand-off to resident myeloid cells. These effects all required CCR7. Live imaging demonstrated direct presentation to T cells in LN, and CCR7 loss specifically in these cells resulted in defective LN T cell priming and increased tumor outgrowth. CCR7 expression levels in human tumors correlate with signatures of CD141(+) DC, intratumoral T cells, and better clinical outcomes. This work identifies an ongoing pathway to T cell priming, which should be harnessed for tumor therapies.
Collapse
Affiliation(s)
- Edward W Roberts
- Department of Pathology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0511, USA
| | - Miranda L Broz
- Department of Pathology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0511, USA
| | - Mikhail Binnewies
- Department of Pathology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0511, USA
| | - Mark B Headley
- Department of Pathology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0511, USA
| | - Amanda E Nelson
- Department of Pathology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0511, USA
| | - Denise M Wolf
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA
| | - Tsuneyasu Kaisho
- Institute of Advanced Medicine, Wakayama Medical University, Wakayama 641-8509, Japan
| | - Dusan Bogunovic
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Nina Bhardwaj
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Matthew F Krummel
- Department of Pathology, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0511, USA.
| |
Collapse
|
11
|
Lelkes E, Headley MB, Thornton EE, Looney MR, Krummel MF. The spatiotemporal cellular dynamics of lung immunity. Trends Immunol 2014; 35:379-86. [PMID: 24974157 DOI: 10.1016/j.it.2014.05.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2013] [Revised: 05/19/2014] [Accepted: 05/21/2014] [Indexed: 01/08/2023]
Abstract
The lung is a complex structure that is interdigitated with immune cells. Understanding the 4D process of normal and defective lung function and immunity has been a centuries-old problem. Challenges intrinsic to the lung have limited adequate microscopic evaluation of its cellular dynamics in real time, until recently. Because of emerging technologies, we now recognize alveolar-to-airway transport of inhaled antigen. We understand the nature of neutrophil entry during lung injury and are learning more about cellular interactions during inflammatory states. Insights are also accumulating in lung development and the metastatic niche of the lung. Here we assess the developing technology of lung imaging, its merits for studies of pathophysiology and areas where further advances are needed.
Collapse
Affiliation(s)
- Efrat Lelkes
- Department of Pediatrics, University of California-San Francisco, 513 Parnassus Avenue, HSW 518, San Francisco, CA 94143-0511, USA; Department of Pathology, University of California-San Francisco, 513 Parnassus Avenue, HSW 518, San Francisco, CA 94143-0511, USA
| | - Mark B Headley
- Department of Pathology, University of California-San Francisco, 513 Parnassus Avenue, HSW 518, San Francisco, CA 94143-0511, USA
| | - Emily E Thornton
- Department of Pathology, University of California-San Francisco, 513 Parnassus Avenue, HSW 518, San Francisco, CA 94143-0511, USA
| | - Mark R Looney
- Department of Medicine, University of California-San Francisco, 513 Parnassus Avenue, HSE 1355A, San Francisco, CA 94143-0511, USA
| | - Matthew F Krummel
- Department of Pathology, University of California-San Francisco, 513 Parnassus Avenue, HSW 518, San Francisco, CA 94143-0511, USA.
| |
Collapse
|
12
|
Miazgowicz MM, Headley MB, Larson RP, Ziegler SF. Thymic stromal lymphopoietin and the pathophysiology of atopic disease. Expert Rev Clin Immunol 2014; 5:547-556. [PMID: 20436950 DOI: 10.1586/eci.09.45] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Thymic stromal lymphopoietin (TSLP) is an IL-7-related cytokine expressed predominantly by barrier epithelial cells. TSLP is a potent activator of several cell types, including myeloid-derived dendritic cells, monocytes/macrophages and mast cells. Recent studies have revealed an important role for TSLP in the initiation and progression of allergic inflammatory diseases. In this review, we will discuss the role of TSLP in atopic diseases, as well as its function in immune homeostasis.
Collapse
Affiliation(s)
- Michael M Miazgowicz
- Immunology Program, Benaroya Research Institute, Seattle, WA, USA and Immunology Department, University of Washington School of Medicine, Seattle, WA, USA and Benaroya Research Institute at Virginia Mason, 1201 Ninth Avenue, Seattle, WA 98101, USA, Tel.: +1 206 583 6525, ,
| | | | | | | |
Collapse
|
13
|
Han H, Headley MB, Xu W, Comeau MR, Zhou B, Ziegler SF. Thymic stromal lymphopoietin amplifies the differentiation of alternatively activated macrophages. J Immunol 2012; 190:904-12. [PMID: 23275605 DOI: 10.4049/jimmunol.1201808] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
The epithelial-derived cytokine thymic stromal lymphopoietin (TSLP) has been associated with the promotion of type 2 inflammation and the induction of allergic disease. In humans TSLP is elevated in the lungs of asthma patients and in the lesional skin of individuals with atopic dermatitis, whereas mice lacking TSLP responses are refractory to models of Th2-driven allergic disease. Although several cell types, including dendritic cells, basophils, and CD4 T cells, have been shown to respond to TSLP, its role in macrophage differentiation has not been studied. Type 2 cytokines (i.e., IL-4 and IL-13) can drive the differentiation of macrophages into alternatively activated macrophages (aaMs, also referred to as M2 macrophages). This population of macrophages is associated with allergic inflammation. We therefore reasoned that TSLP/TSLPR signaling may be involved in the differentiation and activation of aaMs during allergic airway inflammation. In this study, we report that TSLP changes the quiescent phenotype of pulmonary macrophages toward an aaM phenotype during TSLP-induced airway inflammation. This differentiation of airway macrophages was IL-13-, but not IL-4-, dependent. Taken together, we demonstrate in this study that TSLP/TSLPR plays a significant role in the amplification of aaMΦ polarization and chemokine production, thereby contributing to allergic inflammation.
Collapse
Affiliation(s)
- Hongwei Han
- Immunology Program, Benaroya Research Institute, Seattle, WA 98101, USA
| | | | | | | | | | | |
Collapse
|
14
|
Lee HC, Headley MB, Loo YM, Berlin A, Gale M, Debley JS, Lukacs NW, Ziegler SF. Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. J Allergy Clin Immunol 2012; 130:1187-1196.e5. [PMID: 22981788 DOI: 10.1016/j.jaci.2012.07.031] [Citation(s) in RCA: 132] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2011] [Revised: 07/06/2012] [Accepted: 07/09/2012] [Indexed: 12/28/2022]
Abstract
BACKGROUND Respiratory viral infection, including respiratory syncytial virus (RSV) and rhinovirus, has been linked to respiratory disease in pediatric patients, including severe acute bronchiolitis and asthma exacerbation. OBJECTIVE The study examined the role of the epithelial-derived cytokine thymic stromal lymphopoietin (TSLP) in the response to RSV infection. METHODS Infection of human airway epithelial cells was used to examine TSLP induction after RSV infection. Air-liquid interface cultures from healthy children and children with asthma were also tested for TSLP production after infection. Finally, a mouse model was used to directly test the role of TSLP signaling in the response to RSV infection. RESULTS Infection of airway epithelial cells with RSV led to the production of TSLP via activation of an innate signaling pathway that involved retinoic acid induced gene I, interferon promoter-stimulating factor 1, and nuclear factor-κB. Consistent with this observation, airway epithelial cells from asthmatic children a produced significantly greater levels of TSLP after RSV infection than cells from healthy children. In mouse models, RSV-induced TSLP expression was found to be critical for the development of immunopathology. CONCLUSION These findings suggest that RSV can use an innate antiviral signaling pathway to drive a potentially nonproductive immune response and has important implications for the role of TSLP in viral immune responses in general.
Collapse
Affiliation(s)
- Hai-Chon Lee
- Immunology Program, Benaroya Research Institute, Seattle, WA, USA
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Han H, Xu W, Headley MB, Jessup HK, Lee KS, Omori M, Comeau MR, Marshak-Rothstein A, Ziegler SF. Thymic stromal lymphopoietin (TSLP)-mediated dermal inflammation aggravates experimental asthma. Mucosal Immunol 2012; 5:342-51. [PMID: 22354320 PMCID: PMC3328620 DOI: 10.1038/mi.2012.14] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Individuals with one atopic disease are far more likely to develop a second. Approximately half of all atopic dermatitis (AD) patients subsequently develop asthma, particularly those with severe AD. This association, suggesting a role for AD as an entry point for subsequent allergic disease, is a phenomenon known as the "atopic march." Although the underlying cause of the atopic march remains unknown, recent evidence suggests a role for the cytokine thymic stromal lymphopoietin (TSLP). We have established a mouse model to determine whether TSLP plays a role in this phenomenon, and in this study show that mice exposed to the antigen ovalbumin (OVA) in the skin in the presence of TSLP develop severe airway inflammation when later challenged with the same antigen in the lung. Interestingly, neither TSLP production in the lung nor circulating TSLP is required to aggravate the asthma that was induced upon subsequent antigen challenge. However, CD4 T cells are required in the challenge phase of the response, as was challenge with the sensitizing antigen, demonstrating that the response was antigen specific. This study, which provides a clean mouse model to study human atopic march, indicates that skin-derived TSLP may represent an important factor that triggers progression from AD to asthma.
Collapse
Affiliation(s)
- Hongwei Han
- Immunology Program, Benaroya Research Institute, Seattle, Washington 98101, USA
| | - Whitney Xu
- Immunology Program, Benaroya Research Institute, Seattle, Washington 98101, USA
| | - Mark B. Headley
- Immunology Program, Benaroya Research Institute, Seattle, Washington 98101, USA
,Department of Immunology, University of Washington School of Medicine, Seattle, Washington 98195, USA
| | - Heidi K. Jessup
- Inflammation Research, Amgen, Seattle, Washington 98119, USA
| | - Karen S. Lee
- Department of Medicine, Division of Rheumatology University of Massachusetts Medical School, Worcester, MA 01605, USA
| | - Miyuki Omori
- Immunology Program, Benaroya Research Institute, Seattle, Washington 98101, USA
| | | | - Ann Marshak-Rothstein
- Department of Medicine, Division of Rheumatology University of Massachusetts Medical School, Worcester, MA 01605, USA
| | - Steven F. Ziegler
- Immunology Program, Benaroya Research Institute, Seattle, Washington 98101, USA
,Department of Immunology, University of Washington School of Medicine, Seattle, Washington 98195, USA
| |
Collapse
|
16
|
Headley MB, Lee HC, Ziegler SF. RSV-induced expression of TSLP and asthma development (79.13). The Journal of Immunology 2009. [DOI: 10.4049/jimmunol.182.supp.79.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Early infection with Respiratory Syncytial Virus (RSV) has long been recognized to predispose certain individuals towards the development of asthma. The immune response to RSV is unique in that it consists of protective Th1 and immunopathologic Th2-type features. Though much is known about the pathology of this disease it is still unclear how RSV infection leads to asthma development. Thymic Stromal Lymphopoietin (TSLP) is a cytokine that has been shown to be both necessary and sufficient for the development of asthma. Mice that express a lung-specific TSLP transgene (SPC-TSLP) develop a spontaneous and progressive asthma-like disease while TSLPRKO mice are highly resistant to disease in an antigen-specific asthma model. In this study we highlight a possible role for TSLP as the link between RSV infection and asthma development. We demonstrate that TSLP overexpression results in sensitization and the development of allergy to environmental antigens. Further, we show for the first time that RSV and its relative, Sendai Virus, lead to increases in TSLP expression by airway epithelial cells both in vitro and in vivo. Taken together these data suggest that TSLP induced by RSV during primary infection may increase susceptibility or directly result in asthma development. Additionally, in this study we show that the RIG-I viral recognition pathway represents a novel pathway leading to TSLP expression.
Collapse
Affiliation(s)
- Mark B Headley
- 1Immunology, University of Washington - Benaroya Research Institute, Seattle, WA
| | | | | |
Collapse
|
17
|
Headley MB, Zhou B, Shih WX, Aye T, Comeau MR, Ziegler SF. TSLP conditions the lung immune environment for the generation of pathogenic innate and antigen-specific adaptive immune responses. J Immunol 2009; 182:1641-7. [PMID: 19155513 DOI: 10.4049/jimmunol.182.3.1641] [Citation(s) in RCA: 91] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Thymic stromal lymphopoietin (TSLP) is crucial for the development of atopic diseases in humans and mice. Mice that express a lung-specific TSLP transgene (surfactant protein C promoter (SPC)-TSLP) develop a spontaneous and progressive asthma-like disease, suggesting that TSLP expression alone was sufficient for disease development. In this study, we show that, in fact, TSLP alone only causes a weak innate response that is insufficient for development of full airway inflammatory disease. Complete disease development requires both TSLP and antigenic stimulation. These data suggest that the spontaneous lung inflammation observed in SPC-TSLP mice reflects a TSLP-driven predisposition toward the development of aberrant responses against innocuous environmental Ags. This provides evidence that TSLP may act directly to induce susceptibility to the inappropriate allergic responses that characterize atopy and asthma. We additionally show that disease development requires CD4 T cells but not B cells. Further, we reveal a TSLP-driven innate response involving mucus overproduction and goblet cell metaplasia. Taken together, these data suggest a multifaceted model of TSLP-mediated airway inflammation, with an initial activation of resident innate immune cells, followed by activation of the adaptive immune system and full disease development. This study provides new insight into the unique features of the asthma pathology contributed by the innate and adaptive immune responses in response to TSLP stimulation.
Collapse
Affiliation(s)
- Mark B Headley
- Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195, USA
| | | | | | | | | | | |
Collapse
|
18
|
Zhou B, Headley MB, Aye T, Tocker J, Comeau MR, Ziegler SF. Reversal of thymic stromal lymphopoietin-induced airway inflammation through inhibition of Th2 responses. J Immunol 2009; 181:6557-62. [PMID: 18941246 DOI: 10.4049/jimmunol.181.9.6557] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Lung-specific thymic stromal lymphopoietin (TSLP) expression is sufficient for the development of an asthma-like chronic airway inflammatory disease. However, the nature of the downstream pathways that regulate disease development are not known. In this study, we used IL-4- and Stat6-deficient mice to establish the role of Th2-type responses downstream of TSLP. IL-4 deficiency greatly reduced, but did not eliminate, TSLP-induced airway hyperresponsiveness, airway inflammation, eosinophilia, and goblet cell metaplasia, while Stat6 deficiency eliminated these asthma-like symptoms. We further demonstrate, using the chronic model of TSLP-mediated airway inflammation, that blockade of both IL-4 and IL-13 responses, through administration of an anti-IL-4R alpha mAb, reversed asthma-like symptoms, when given to mice with established disease. Collectively these data provide insight into the pathways engaged in TSLP-driven airway inflammation and demonstrate that simultaneous blockade of IL-4 and IL-13 can reverse established airway disease, suggesting that this may be an effective approach for the therapy of Th2-mediated inflammatory respiratory disease.
Collapse
Affiliation(s)
- Baohua Zhou
- Immunology Program, Benaroya Research Institute, Seattle, WA 98101, USA.
| | | | | | | | | | | |
Collapse
|
19
|
Lee HC, Headley MB, Iseki M, Ikuta K, Ziegler SF. Cutting edge: Inhibition of NF-kappaB-mediated TSLP expression by retinoid X receptor. J Immunol 2008; 181:5189-93. [PMID: 18832669 DOI: 10.4049/jimmunol.181.8.5189] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The epithelial-derived cytokine thymic stromal lymphopoietin (TSLP) has important roles in the initiation of allergic airway inflammation and the activation of dendritic cells. We have shown that the human TSLP gene is regulated in a NF-kappaB-dependent manner; however the factors that negatively regulate TSLP expression are not known. In this study we demonstrate that 9-cis-retinoic acid (9-cis-RA) is a negative regulator of TSLP expression in airway epithelial cells. This inhibition is manifested as a block in the IL-1beta-mediated recruitment of NF-kappaB to the human TSLP promoter. 9-cis-RA-mediated inhibition is not restricted to TSLP gene expression but rather reflects a general inhibition of NF-kappaB activation, as other NF-kappaB-regulated-genes were also inhibited in a similar manner by 9-cis-RA treatment. Taken as a whole, these data demonstrate that inhibition of IL-1beta-dependent genes by active retinoid X receptors involves antagonism of NF-kappaB signaling.
Collapse
Affiliation(s)
- Hai-Chon Lee
- Immunology Program, Benaroya Research Institute, Seattle, WA 98101, USA
| | | | | | | | | |
Collapse
|
20
|
Olson RD, Headley MB, Hodzic A, Walsh GM, Wingett DG. In vitro and in vivo immunosuppressive activity of a novel anthracycline, 13-deoxy, 5-iminodoxorubicin. Int Immunopharmacol 2007; 7:734-43. [PMID: 17466907 PMCID: PMC2002547 DOI: 10.1016/j.intimp.2007.01.010] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2006] [Revised: 01/16/2007] [Accepted: 01/17/2007] [Indexed: 11/23/2022]
Abstract
We report that the novel anthracycline analog, 13-deoxy, 5-iminodoxorubicin (DIDOX), represents a potentially new class of immunosuppressive agents. DIDOX has been structurally modified from the parent compound, doxorubicin, to remove the carbonyl group at carbon-13 and the quinone moiety at carbon-5 since these structures likely mediate the cardiotoxic side effects of this family of chemotherapeutic drugs. Our studies demonstrate that DIDOX inhibits T cell proliferation and the expression of the T cell activation molecules, CD25 and CD40L. DIDOX also inhibits the production of the pro-inflammatory cytokine, TNF-alpha and IL-2. Studies using animal models demonstrate that DIDOX inhibits the inflammation accompanying contact hypersensitivity reactions and possesses reduced cardiotoxicity compared to doxorubicin. These findings indicate that DIDOX has important immunosuppressive activities that may warrant the development of this new and improved anthracycline for the treatment of T cell-mediated inflammatory diseases.
Collapse
Affiliation(s)
- Richard D. Olson
- Boise VA Medical Center, Research Service, 500 W. Fort St., Boise, ID 83702
| | - Mark B. Headley
- Boise State University, Department Biology, 1910 University Dr., Boise, ID 83725
| | - Alma Hodzic
- Boise State University, Department Biology, 1910 University Dr., Boise, ID 83725
| | | | - Denise G. Wingett
- Boise State University, Department Biology, 1910 University Dr., Boise, ID 83725
- * Corresponding author: Boise State University, Department of Biology, 1910 University Dr., Boise, ID 83725. Tel.: 001 208 426 2921; fax: 001 208 426 4267, E-mail address: (D.G. Wingett)
| |
Collapse
|